Equity Analysis /
United States of America

US : NGM Biopharmaceuticals, Inc. - NGM | Upgrade to Strong Buy: Complement Validated in GA; NGM120 Data Next Week at ESMO

    Contributors
    Ryan Deschner
    Timur Ivannikov
    CGS-CIMB
    12 September 2021
    Published by